<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04067505</url>
  </required_header>
  <id_info>
    <org_study_id>SAHZhejiangU-001</org_study_id>
    <nct_id>NCT04067505</nct_id>
  </id_info>
  <brief_title>Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study</brief_title>
  <acronym>PLICTS</acronym>
  <official_title>An Efficacy and Safety Study of Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression Treated With Stent Implantation (PLICTS)ï¼šA Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huadong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai 5th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yantai Yuhuangding Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Xiaoshan hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of rivaroxaban for the&#xD;
      prevention of deep vein thrombosis in patients with left iliac vein compression treated with&#xD;
      stent implantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Left Iliac Vein Compression Syndrome (LIVCS) is a disease of iliac vein stenosis/occlusion&#xD;
      caused by chronic friction and compression of the left iliac vein by the right common iliac&#xD;
      artery and lumbar vertebra. It is also called Cockett syndrome or May-Thurner syndrome.&#xD;
      Recently, left iliac vein balloon dilatation with stent implantation have been used to treat&#xD;
      patients with LIVCS, and have achieved good results. However, no matter the iliac vein&#xD;
      stenosis or occlusion, interventional therapy can directly cause local trauma and intimal&#xD;
      injury, which is a clear inducement of local thrombosis. Therefore, high intensity&#xD;
      anticoagulation therapy is still needed to prevent secondary thrombosis in stent after left&#xD;
      iliac vein balloon dilatation with stent implantation. At present, the postoperative&#xD;
      anticoagulation regimen of these patients is early heparin anticoagulant therapy, and later&#xD;
      warfarin anticoagulant therapy. However, due to the narrow therapeutic window of the drug,&#xD;
      patients need to adjust the dosage according to coagulation function under the guidance of&#xD;
      doctors. Rivaroxaban can simplify treatment, and is safe. Previous studies have shown that&#xD;
      rivaroxaban is effective in preventing deep venous thrombosis after orthopaedic surgery.&#xD;
      Rivaroxaban has also been shown to be safe and effective in anticoagulation therapy for&#xD;
      patients with deep venous thrombosis and pulmonary embolism. However, Rivaroxaban lacks&#xD;
      sufficient clinical data for adjuvant anticoagulation therapy after balloon dilatation with&#xD;
      stent implantation. Therefore, this study should be carried out to provide the basis for&#xD;
      LIVCS treatment guidelines and explore the clinical indications of rivaroxaban.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>stent occlusion rate</measure>
    <time_frame>2 year after operation</time_frame>
    <description>Stent occlusion is defined as DS &gt; 50% for each modality with no procedure performed on the treated segment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Change Scale Survey Results</measure>
    <time_frame>1, 3, 6, 12, 18 and 24 months after operation</time_frame>
    <description>Quality of life will be assessed by MOS item short-form health survey scale (SF-36). SF-36 includes eight subscales: physical functioning (PF, 10 items), role limitations due to physical health problems (RL-P, 4 items), bodily pain (BP, 2 items), general health (GH, 5 items), vitality (V, 4 items), social functioning (SF, 2 items), role limitations due to emotional problems (RL-E, 3 items) and mental health (MH, 5 items). The vitality sub-score assesses energy and fatigue, and ranges from 0 (worst) - 100 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>1, 3, 6, 12, 18 and 24 months after operation</time_frame>
    <description>Percentage of participants with all deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anticoagulation raleted mortality</measure>
    <time_frame>1, 3, 6, 12, 18 and 24 months after operation</time_frame>
    <description>Percentage of participants with anticoagulation raleted deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with stent displacement/fracture</measure>
    <time_frame>1, 3, 6, 12, 18 and 24 months after operation</time_frame>
    <description>Events will be assessed based on computed tomography (CT) or X ray</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with hemorrhage</measure>
    <time_frame>1, 3, 6, 12, 18 and 24 months after operation</time_frame>
    <description>Including hemorrhagic stroke, gastrointestinal bleeding, hematuria, mucocutaneous hemorrhage and other visceral bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with other vascular events</measure>
    <time_frame>1, 3, 6, 12, 18 and 24 months after operation</time_frame>
    <description>All vascular events (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, acute coronary syndrome, unstable angina, ischemic stroke, transient ischemic attack, pulmonary embolism, non-central nervous system systemic embolism or vascular death) will be assessed based results/films/images of confirmatory testing, and/or case summaries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with thrombosis</measure>
    <time_frame>1, 3, 6, 12, 18 and 24 months after operation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">224</enrollment>
  <condition>May-Thurner Syndrome</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive rivaroxaban 15mg twice daily for three weeks, then 20mg oral once daily after operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin/Nadroparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive nadroparin 1mg/kg twice daily (subcutaneous), plus warfarin 3mg oral once daily for 5 days after the operation, later warfarin(oral) at individually titrated doses(0.75mg to 18mg) to achieve a target international normalized ratio (INR) of 2.0 to 3.0, once daily until 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Dose: 15mg twice daily for three weeks, then 20mg once daily until six months after the operation. Application: oral</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Dose: 3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until 6 months Duration: 6 months Frequency: once daily Application: oral</description>
    <arm_group_label>Warfarin/Nadroparin</arm_group_label>
    <other_name>coumadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nadroparin</intervention_name>
    <description>Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous</description>
    <arm_group_label>Warfarin/Nadroparin</arm_group_label>
    <other_name>Fraxiparin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with thrombotic left iliac vein compression syndrome who underwent left iliac&#xD;
             vein stent implantation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years or age &gt; 75 years&#xD;
&#xD;
          -  With history of pelvic surgery, left iliac vein trauma and pelvic radiotherapy&#xD;
&#xD;
          -  With obvious contraindications for anticoagulation therapy&#xD;
&#xD;
          -  Allergic to iodine contrast agents in the past&#xD;
&#xD;
          -  With concomitant diseases that need high-intensity anticoagulation, and the&#xD;
             anticoagulation intensity is clearly higher than that of the patients with iliac vein&#xD;
             therapy alone&#xD;
&#xD;
          -  Active bleeding or potential bleeding risk&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  With pelvic tumors causing compression of left iliac vein,&#xD;
&#xD;
          -  With chronic venous insufficiency of lower extremities caused by K-T syndrome&#xD;
&#xD;
          -  With malignant tumors and life expectancy &lt; 1 year&#xD;
&#xD;
          -  Taking cytochrome P450 3A4(CYP-450 3A4) inhibitors or inducers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhejie Liu, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Yin</last_name>
    <phone>86-0571-87913706</phone>
    <email>lawson4001@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhengdong Fang</last_name>
      <phone>15256990126</phone>
      <phone_ext>86</phone_ext>
      <email>fangzhengdong@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yantai Yuhuangding Hospital</name>
      <address>
        <city>Yantai</city>
        <state>Shangdong</state>
        <zip>264000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lubin Li, MD</last_name>
      <phone>18653587255</phone>
      <phone_ext>86</phone_ext>
      <email>278468192@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huadong Hospital affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wan Zhang, MD,PhD</last_name>
      <phone>13916056910</phone>
      <phone_ext>86</phone_ext>
      <email>ant0930@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai 5th People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin Gao, MD,PhD</last_name>
      <phone>13764979078</phone>
      <phone_ext>86</phone_ext>
      <email>doctorgaobin@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianing Yue, MD,PhD</last_name>
      <phone>13564788422</phone>
      <phone_ext>86</phone_ext>
      <email>yuejianing@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuefeng Zhu, MD</last_name>
      <phone>13868101010</phone>
      <phone_ext>86</phone_ext>
      <email>drzyf@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The second affiliated hospital of zhejiang university school of medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhejie Liu, MD,PhD</last_name>
      <phone>15268135830</phone>
      <phone_ext>86</phone_ext>
      <email>lawson3001@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial people's hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guangwei Yang</last_name>
      <phone>13758146564</phone>
      <email>ygw_zju@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Xiaoshan Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Han</last_name>
      <phone>18957113906</phone>
      <email>hw9453@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Liu Z, Gao N, Shen L, Yang J, Zhu Y, Li Z, Si Y. Endovascular treatment for symptomatic iliac vein compression syndrome: a prospective consecutive series of 48 patients. Ann Vasc Surg. 2014 Apr;28(3):695-704. doi: 10.1016/j.avsg.2013.05.019. Epub 2013 Oct 27.</citation>
    <PMID>24559785</PMID>
  </reference>
  <reference>
    <citation>O'Sullivan GJ, Semba CP, Bittner CA, Kee ST, Razavi MK, Sze DY, Dake MD. Endovascular management of iliac vein compression (May-Thurner) syndrome. J Vasc Interv Radiol. 2000 Jul-Aug;11(7):823-36.</citation>
    <PMID>10928517</PMID>
  </reference>
  <reference>
    <citation>Hurst DR, Forauer AR, Bloom JR, Greenfield LJ, Wakefield TW, Williams DM. Diagnosis and endovascular treatment of iliocaval compression syndrome. J Vasc Surg. 2001 Jul;34(1):106-13.</citation>
    <PMID>11436082</PMID>
  </reference>
  <reference>
    <citation>Eriksson BI, Kakkar AK, Turpie AG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br. 2009 May;91(5):636-44. doi: 10.1302/0301-620X.91B5.21691. Erratum in: J Bone Joint Surg Br. 2009 Aug;91(8):1120.</citation>
    <PMID>19407299</PMID>
  </reference>
  <reference>
    <citation>Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009 May 16;373(9676):1673-80. doi: 10.1016/S0140-6736(09)60734-0. Epub 2009 May 4.</citation>
    <PMID>19411100</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 24, 2019</study_first_submitted>
  <study_first_submitted_qc>August 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>December 29, 2020</last_update_submitted>
  <last_update_submitted_qc>December 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</investigator_affiliation>
    <investigator_full_name>Zhenjie Liu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>May-Thurner Syndrome</keyword>
  <keyword>warfarin</keyword>
  <keyword>rivaroxaban</keyword>
  <keyword>stent implantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>May-Thurner Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nadroparin</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

